Excipient Variability Sources, Importance and Potential Impact Chris Moreton, Ph.D Past Chair IPEC-Americas Partner – FinnBrit Consulting

Slides:



Advertisements
Similar presentations
Dr. Birgit Schmauser, BfArM, Bonn
Advertisements

Stability Studies - Evaluation of Outcomes and Development of Documentation For Regulatory Submissions Bob Seevers.
Coal to Liquids Plant Site Selection in WV Douglas G. Patchen October 25, 2007.
Identifying Manure and Compost Export Markets in Montana: to Improve Nutrient Balance on Animal Feeding Operations Background: The current model of animal.
Statistical Approaches to Addressing the Requirements of the New FDA Process Validation Guidance for Small Molecules 1 Jason Marlin, MS/T Statistics, Eli.
Finished Pharmaceutical Product Specifications
Atypical Actives PDA-FDA Conference March 9-10, 2011 David R. Schoneker
By Timina Olive Kayaviri Supervisor : Dr. Amugune
1 Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS,
Stability data required by WHO-PQP Mercy Acquaye.
THE CONTEXT OF LOGISTICS. Cycle of Supply and Demand Customers Other Inputs Other Outputs Operations Demand for Products Supply of Products passed to.
Chemistry, Manufacturing, and Controls (CMC) and Good Manufacturing Practices (GMPs): The Big Picture of a Long-term Commitment Elizabeth Pollina Cormier,
Determine impurity level in relevant batches1
Kyiv, TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence.
Delivering sustainable solutions in a more competitive world Carbon Footprinting: Methodological Approaches, Challenges & Opportunities Simon Aumônier.
Drying in the Pharmaceutical Industry1 DIT- Msc Pharmaceutical and Chemical Processes Technologies 28 th April 2009 Sara Baeza.
Supply Chain Design Problem Tuukka Puranen Postgraduate Seminar in Information Technology Wednesday, March 26, 2009.
Quality control of raw materials In-process control
Slide 1 of 19D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
Pharmaceutical Product Quality Assurance Through CMC Drug Development Process Presented by Darlene Rosario (Aradigm) 21 October 2003 Meeting of the Advisory.
Reference, Retention and Reserve Samples
VINOD P. SHAH, PH.D. SENIOR RESEARCH SCIENTIST OFFICE OF PHARMACEUTICAL SCIENCE CENTER FOR DRUG EVALUATION AND RESEARCH FOOD AND DRUG ADMINISTRATION Pharmacy.
MIT PHARMACEUTICAL MANUFACTURING INITIATIVE (PHARMI) PHARMACEUTICAL MANUFACTURING: NEW TECHNOLOGY OPPORTUNITIES.. G.K.Raju, Ph.D. Executive Director, Pharmaceutical.
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Regulatory Requirement on Dossier of Medicinal.
QUALITY CONTROL OF PHYSICO-Chemical METHODS Introduction :Validation توثيق المصدوقية.
Interchangeability and study design Drs. Jan Welink Training workshop: Training of BE assessors, Kiev, October 2009.
World Health Organization
Application of the principles of QbD in vaccines production Andrea Pranti.
Achieving and Demonstrating “Quality-by-Design” with Respect to Drug Release/dissolution Performance for Conventional or Immediate Release Solid Oral Dosage.
Accelerated Stability Testing
Quality by Design Application of Pharmaceutical QbD for Enhancement of the Solubility and Dissolution of a Class II BCS Drug using Polymeric Surfactants.
The following minimum specified ranges should be considered: Drug substance or a finished (drug) product 80 to 120 % of the test concentration Content.
07/26/2010 National Petroleum Council Future Transportation Fuels Study - Biofuels Subgroup Framing Questions 1.
Excipient QbD Concepts to Enhance the Development of Robust Drug Products Priscilla S. Zawislak Global Regulatory Affairs Manager - Ashland Inc. Chair.
Module 1, Part 3: Process validation Slide 1 of 22 © WHO – EDM – 12/2001 Validation Part 3: Process validation Supplementary Training Modules on Good Manufacturing.
DO NOW Journal Entry – answer the following: Journal Entry – answer the following: What is environmental science?
Quality by Design (QbD) Myth : An expensive development tool ! Fact : A tool that makes product development and commercial scale manufacturing simple !
1-7.The ICH Q8 “Minimal Approach” to Pharmaceutical Development
US Downstream Industry Outlook and Opportunities LSU Energy Summit 2004 October 21, 2004 Gil Nebeker Purvin & Gertz, Inc. LSU Energy Summit 2004 October.
BNF for children and formulations Ian Costello British National Formulary.
Critical Material Properties for Pharmaceutical Dosage Forms - Industry Perspective Tony Hlinak Abbott Laboratories North Chicago, IL.
Molecule-to-Market-Place Quality
HELM AG Module 3 Christa Clasen Ankara, 6./7. April 2006.
Workshop Session 3 Questions 1 How would a control strategy look different in a traditional submission vs a QbD submission? How would parameters that are.
CHEE 4401 Definitions drug - any substance that affects the structure or functioning of an organism pharmaceutics - the area of study concerned with the.
Excipient Composition and Performance-Related Properties of Excipients Chris Moreton, Ph.D. FinnBrit Consulting IPEC-Americas FDA Seminar, October 21,
Some Future Developments Brian Carlin, Ph.D FMC Chris Moreton, Ph.D FinnBrit Consulting IPEC-Americas FDA Seminar, October 21,
Satish Mallya January 20-22, |1 | 2-3. Pharmaceutical Development Satish Mallya Quality Workshop, Copenhagen May 18-21, 2014 May 18-21,2014.
National Action Planning – a game of two halves? Looking back: Where we are now? What are the key issues? Looking forward: Where do we want to be? How.
Location Planning and Analysis Copyright © 2015 McGraw-Hill Education. All rights reserved. No reproduction or distribution without the prior written consent.
General Aspects of Quality assessment of multisource interchangeable medicines Rutendo Kuwana Technical Officer, WHO, Geneva Training workshop: Assessment.
Forecasting for Water Resources Planning. Learning Objective(s):  The student will:  Understand the need for forecasts.  Be able to describe what a.
Irrigation – Does Variability Matter? Irrigation – Does Variability Matter? Ian McIndoe Fraser Scales.
Process Analytical Technologies (PATs), Applications and Benefits Working Group.
FDA PAT Sub-Committee of Advisory Committee for Pharmaceutical Sciences June 12-13, 2002; Gaithersburg, MD Regulatory Challenges: Post-Approval PAT Applications.
GREEN CHEMISTRY 2010/2011. background… Taken in large part from Paul L. Bishop’s Pollution Prevention – Fundamentals & Practice, Chapter 9.
开发报批美国 FDA 的仿制药 与相关问题探讨 上海复星普适医药科技有限公司何平. 内容提要 开发仿制药的重要性和机遇 开发仿制药的重要性和机遇 开发仿制药的挑战 开发仿制药的挑战 申报仿制药的分类 申报仿制药的分类 仿制药研发团队 仿制药研发团队 仿制药的研发过程 仿制药的研发过程 QbD 在制剂开发中怎么体现.
+ Standards & Quality Assurance Cindy Orser PhD 2.
Product & Process Working Group February 26, 2002.
Ben Dyson Earth Supply Ltd Alternative feedstock for sustainable growing media: Compost.
Financing Sustainable Farming Olaf Weber Export Development Canada Chair in Environmental Finance
Integration of Excipients into the Design of Experiments for Pharmaceutical Product and Design Space Development Chris Moreton, Ph.D. FinnBrit Consulting.
HOLD-TIME STUDIES.
STABILITY ?.
Foundations of Technology Standard 15
Quality Assurance and Quality Control in Generics
Dr. Birgit Schmauser, BfArM, Bonn
Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER.
Construction Supply Chain Modeling: Issues and Perspectives (Part 1)
Quality guidelines on impurities
Presentation transcript:

Excipient Variability Sources, Importance and Potential Impact Chris Moreton, Ph.D Past Chair IPEC-Americas Partner – FinnBrit Consulting 1

Presentation Outline Background Why excipient variability is important How excipient variability can arise Options for addressing excipient variability 2

The Objective To manufacture robust medicines that deliver the drug to the patient: – In the required amount (content and assay). – At the optimum rate necessary to achieve the desired therapeutic benefit (in vivo dissolution). – Consistently: Within lots (blend uniformity for all components). Between lots (validated manufacturing process). – For the shelf life of the product (stability). At the same time, the development process has to be efficient. 3

Components of a medicinal product 4

Why is excipient variability important? Excipients are important components of drug products. Excipient variability may impact drug product variability. – But excipients are not the only sources of drug product variability API and process parameters may also be sources of product variability. 5

Excipient Variability There is inherent variability in everything: – Excipients are no exception. Why is it important? – It can contribute to product variability. But it is not the only potential source of product variability! 6

Excipient Variability We can sometimes see the effect of excipient variability in failed batches, but We cannot always control excipient variability adequately Why? – How does excipient variability arise? 7

Sources of Excipient Variability Many excipients are natural products, or derived from natural products. – Source of feedstock (crop) Species/varietal Soil composition Use of fertilizer – Weather is changeable Conditions during the growing season Conditions during harvesting Conditions during transportation to the processing site Conditions during storage of the crude feedstock Conditions during processing Conditions during packaging, storage and distribution 8

Sources of Excipient Variability Even for synthetic materials: – There is a misconception that synthetic or semi- synthetic materials are less variable than natural products It depends on the chemical processing – Single phase or multiphase, etc. – Most synthetic materials are derived from crude oil or gas which varies with location of the well: Content of sulfur Content and range of heavy metals Distribution of the different organic components 9

Sources of Excipient Variability Manufacturing process – Scale of manufacture Excipients frequently manufactured using continuous processing. – Location of manufacturing site Different scale of manufacture at different sites. – Alternate processes used by different manufacturers. Anti-oxidant vs. inert gas blanket – Normal wear and tear of the equipment train Supply chain – Type of transportation – Duration – Storage conditions en route 10

Excipient Variability We have to accept that there will be variability. We need to come to terms with it. Options may include: – Designing more robust formulations to cope with variability QbD will help – Using processing end-points to compensate for materials variability. 11

What is a Robust Formulation? A formulation that is able to accommodate the typical variability seen in: – API – Excipients – Processes Without compromising the manufacture, stability, performance or any other attribute of the product critical to the patient’s care or well being. 12

Formulation variability – a Simplistic View Bulk Active Drug Variability Excipients Variability Process Variability Product Variability 13

Formulation variability – a Wrong View Bulk Active Drug Variability Excipients Variability Process Variability Product Variability 14

In reality! Bulk Active Drug Variability Excipients Variability Process Variability Product Variability 15

Interactions in Product Manufacture Interactions include: – Powder – Powder – Liquid – Powder – Equipment – Liquid – Equipment For each unit process – Powder – Operator – Liquid – Operator – Equipment – Operator – etc. For each component 16

Which type of variability applies to our application? Batch number/Time of output Raw material parameter    17

Raw Material Variability Raw material Parameter Raw material batches 18

Raw Material Variability: Acceptable Raw material Parameter Raw material batches 19

Raw Material Variability: Possibly acceptable Raw material Parameter Raw material batches 20

Raw Material Variability: Impossible limits Raw material Parameter Raw material batches 21

Conclusions Excipient variability is important. There is inherent variability in excipients arising from a variety of possible sources. Designing product formulations and setting excipient specifications that do not allow for the inherent variability of the excipient is a recipe for disaster. 22

Thank you! We will now answer Questions. 23